Midwest Stone Institute began in 1985 to provide Extracorporeal Shockwave Lithotripsy (ESWL) for the treatment of kidney stones. Since this time, more than 12,000 patients have experienced the miracle of ESWL through the auspices of Midwest Stone Institute.
In 1998, Midwest Stone Institute participated in the FDA trial of the OssaTron® shockwave technology for musculoskeletal conditions. Those trials led to the 2000 FDA approval of shockwave therapy for the treatment of chronic proximal plantar fasciitis (heel pain) and the 2002 approval of shockwave therapy for the treatment of lateral epicondylitis (tennis elbow). Midwest Therapy, which was established in 2000, has trained and certified more than 100 local orthopedic and podiatric surgeons to provide the Ossatron® treatment.
Midwest Stone Institute began Midwest Therapy as a limited liability company in 2002.